Career history of Thomas R. Ulich
Former positions of Thomas R. Ulich
| Companies | Position | Start | End |
|---|---|---|---|
| INVIVO THERAPEUTICS HOLDINGS CORP. | Chief Tech/Sci/R&D Officer | 2014-02-23 | 2017-08-29 |
ConjuChem Biotechnologies, Inc. /Old/
 ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | Chief Tech/Sci/R&D Officer | 2005-12-31 | 2009-12-31 |
| ALNYLAM PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2002-12-31 | 2003-12-31 |
Amgen Canada, Inc.
 Amgen Canada, Inc. BiotechnologyHealth Technology Amgen Canada, Inc. operates as a biotechnology company. The company was founded in 1991 and is headquartered in Mississauga, Canada. | Chief Tech/Sci/R&D Officer | 1992-12-31 | 2000-12-31 |
ConjuChem Biotechnologies, Inc.
 ConjuChem Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals. Its peptide products are used to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. ConjuChem Biotechnologies is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. The company was founded on August 25, 2009 and is headquartered in Montréal, Canada. | Chief Tech/Sci/R&D Officer | 2010-01-12 | - |
| Wayne State University (Michigan) | Corporate Officer/Principal | - | - |
| University of California, Berkeley | Corporate Officer/Principal | - | - |
Training of Thomas R. Ulich
| Dartmouth College | Undergraduate Degree |
| David Geffen School of Medicine | Doctorate Degree |
Statistics
International
| United States | 7 |
| Canada | 4 |
Operational
| Chief Tech/Sci/R&D Officer | 5 |
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 5 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| INVIVO THERAPEUTICS HOLDINGS CORP. | Health Technology |
| Private companies | 3 |
|---|---|
ConjuChem Biotechnologies, Inc. /Old/
ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | Health Technology |
ConjuChem Biotechnologies, Inc.
ConjuChem Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals. Its peptide products are used to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. ConjuChem Biotechnologies is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. The company was founded on August 25, 2009 and is headquartered in Montréal, Canada. | Health Technology |
Amgen Canada, Inc.
Amgen Canada, Inc. BiotechnologyHealth Technology Amgen Canada, Inc. operates as a biotechnology company. The company was founded in 1991 and is headquartered in Mississauga, Canada. | Health Technology |
- Stock Market
- Insiders
- Thomas R. Ulich
- Experience
